Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Kiana Burran
CONTACT
Lead
British Columbia Cancer Agency
With
PURPOSE: To determine the safety of de-escalated/optimized adjuvant treatment of patients with CEOC directed by tumor molecular status and strictly defined pathology criteria. HYPOTHESIS: Molecular classification in combination with carefully selected and restricted pathological features will identify a subset of patients with CEOCs who are at very low risk of disease recurrence and are candidates for de-escalated/optimized adjuvant therapy. JUSTIFICATION: CEOC patients are often given chemotherapy +/- pelvic radiation, despite unclear benefit and substantial toxicity from short and long termshort- and long-term treatment-related side effects, such as neuropathy, fatigue and cognitive issues. Overtreatment also results in financial challenges for patients from loss of income, travel expenses related to many appointments and delayed return to work. Although the World Health Organization created a new substage within the endometrial cancer staging system to support the delivery of less (or no) treatment for CEOC patients based on pathology criteria that supports favourable outcomes, studies have shown that molecular features of endometrial cancer can also be used to identify a subset of CEOC patients at very low risk of recurrence who can be directed to treatment de-escalation. In order to further evaluate these findings and change clinical practice, a prospective trial is needed to assess the safety of de-escalated treatment for CEOC patients. RESEARCH DESIGN: This is a phase II, prospective, multi-centre, trial where pathologic and molecular features will be used to identify patients who can be offered de-escalated therapy. Molecular classification- assessing immunohistochemistry for MMR, p53, and ER status in the endometrium and ovarian tumors will be performed. Next generation sequencing for POLE mutation status is needed at least in the endometrial sample. Molecular criteria to define low risk CEOCs will include POLEmut, ER strong + NSMP, and MSH2/MSH6 or PMS2 loss (MMRd without MLH1 promoter hypermethylation) and provided pathologic criteria are also met would enable patients to be considered for de-escalation. Intermediate and high risk carcinomas, encompassing MLH1 promoter methylated, ER-negative NSMP and p53abn CEOCs would not be enrolled. The first site will open in BC, Canada. Due to this rare patient population, other high-volume national and international centers will be sought. Collaborating centers will be selected based on access to molecular testing and interest in providing their CEOC patients with the opportunity to participate in this trial. The aim of this trial is to assess the safety of de-escalated adjuvant treatment in CEOC patients. Patients that fit the eligibility criteria will have the option of choosing to receive treatment de-escalation (no chemotherapy or radiation) vs. additional treatment (chemotherapy +/- radiation) following their primary staging surgery. Recruitment will take place over 3 years from November 1, 2026 - November 1, 2029. Participants will be followed for 3 years after their enrollment after surgery. Baseline Measures: 1. Imaging: If a patient has not had imaging performed on their chest, abdomen and pelvis within 60 days prior to trial enrollment, the patient's gynecologic oncologist will order this imaging to be done within five weeks after trial enrollment. Accepted imaging modalities are (CT, chest x-ray, MRI, PET). Note that imaging prior to surgery is standard of care. 2. Questionnaires: Upon signing the consent form (baseline), patients will be prompted to complete 3 questionnaires about their quality of life and their thoughts regarding their treatment decision (active surveillance vs. additional treatment): 1\. EORTC QLQ-30 2. FCRI-SF 3. EQ-5D-5L These questionnaires will be administered through an online platform for the participant to complete on their own device or on a tablet/laptop provided by the study team. Physical copies will be made available upon patient request. If patient's do not speak English or feel comfortable completing the questionnaires in English, the study coordinator will attempt to obtain these questionnaires in the patient's preferred language. Follow-Up Measures: 1. Imaging: Imaging of the patient's chest, abdomen, and pelvis will be ordered 36 months after enrollment. Although the exact timepoints after surgery are up to the doctor's discretion, additional imaging post-surgery is a part of a patient's standard of care. 2. Questionnaires: Patients will complete the three questionnaires listed above at enrollment, 4, 12, 24, \& 36 months after enrollment. These questionnaires will be administered at patients follow-up appts or through an online platform. 3. Symptom History \& Physical exam: It is standard of care to review patient symptoms and perform abdominal and pelvic examinations during their follow-up appts. This will be recorded by the patient's oncologist within their clinical note. The local study coordinator will review the clinic note and record the outcomes of this symptom review and physical exam within that patient's record on the data collection platform. Recurrence: If a patient's cancer recurs within the 3 year follow-up period, patients will undergo the following study procedures annually from the date of recurrence: 1. Two questionnaires (EORTC QLQ-30 \& EQ-5D-5L) 2. Symptom History \& Physical exam STATISTICAL ANALYSIS: Assuming 68 patients with molecularly stratified CEOC (exclusion of exclusion of MMRd with MLH1 immunohistochemistry loss or MLH1 promoter hypermethylation, p53abn and NSMP ER negative-low) are accrued over 3 years and followed for 3 years, the total person-years of follow-up would be 306 and the upper 95% confidence limit for the true 3-year pelvic recurrence rate would be 7% when the observed 3-year pelvic recurrence rate is 4% from CEOCs in this cohort. Therefore, a true 3-year pelvic recurrence rate of 7%, which for this trial is considered unacceptably high, can be ruled out with 95% confidence in this cohort. Allowing that \~5% of patients may be lost to follow up and 25% of patients may not elect to undergo de-escalated therapy (e.g., will be treated, not counting towards n=68), we estimate needing to enroll \~90 patients to yield 68 evaluable receiving de-escalation. As the statistical analysis has been designed to demonstrate the safety of de-escalation within the group of patients that received no additional treatment, patients who receive adjuvant treatment following surgery are not part of this trial's statistical analysis.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
